ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3

Esta invención se refiere a espiro azepan oxazolidinonas como bloqueadores del canal de calcio Kv1.3 voltaje dependiente, a composiciones farmacéuticas que contienen estos compuestos, a métodos para preparar los compuestos, a métodos para preparar nuevos compuestos intermedios útiles para su síntesi...

Full description

Saved in:
Bibliographic Details
Main Authors LANGE, JOSEPHUS H.M, KOEHLER, KONRAD F, NUNEZ-GARCIA, SARA, MLINARIC, MICHAEL, SMID, PIETER, WEGENER, ELMAR
Format Patent
LanguageSpanish
Published 27.10.2011
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Esta invención se refiere a espiro azepan oxazolidinonas como bloqueadores del canal de calcio Kv1.3 voltaje dependiente, a composiciones farmacéuticas que contienen estos compuestos, a métodos para preparar los compuestos, a métodos para preparar nuevos compuestos intermedios útiles para su síntesis, y a métodos para preparar composiciones. This invention concerns spiro azepane-ox-azolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in the treatment of diabetes, psoriasis, obesity, transplant rejection and inflammatory neuropathies, including T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The compounds have formula (1): wherein R1, R2, (R3)n, and (R4)m have the meanings given in the specification.
Bibliography:Application Number: CR20110000302